文献类型：期刊文献

英文题名：DPP-4 inhibitors for the treatment of type 2 diabetes: a methodology overview of systematic reviews

作者：Ling, Juan[1,2,3,4];Ge, Long[1,2,3,4,5];Zhang, Ding-hua[6];Wang, Yong-feng[7];Xie, Zhuo-lin[8];Tian, Jin-hui[1,2,3,4];Xiao, Xiao-hui[9];Yang, Ke-hu[1,2,3,4]

第一作者：Ling, Juan

通信作者：Yang, KH[1];Yang, KH[2];Yang, KH[3];Yang, KH[4];Xiao, XH[5]

机构：[1]Lanzhou Univ, Sch Basic Med Sci, Evidence Based Med Ctr, Lanzhou, Gansu, Peoples R China;[2]Key Lab Evidence Based Med & Knowledge Translat G, Lanzhou, Gansu, Peoples R China;[3]Lanzhou Univ, Chinese GRADE Ctr, Lanzhou, Gansu, Peoples R China;[4]WHO Collaborating Ctr Guideline Implementat & Kno, Lanzhou, Gansu, Peoples R China;[5]Lanzhou Univ, Clin Med Coll 1, Lanzhou, Gansu, Peoples R China;[6]Gansu Univ Tradit Chinese Med, Lanzhou, Gansu, Peoples R China;[7]Gansu Univ Tradit Chinese Med, Sch Basic Med Sci, Lanzhou, Gansu, Peoples R China;[8]Gansu Prov Hosp Tradit Chinese Med, Dept Endocrinol, Lanzhou, Gansu, Peoples R China;[9]Gansu Prov Peoples Hosp, Lanzhou, Gansu, Peoples R China

第一机构：Lanzhou Univ, Sch Basic Med Sci, Evidence Based Med Ctr, Lanzhou, Gansu, Peoples R China

通信机构：[1]corresponding author), Lanzhou Univ, Sch Basic Med Sci, Evidence Based Med Ctr, Lanzhou, Gansu, Peoples R China;[2]corresponding author), Key Lab Evidence Based Med & Knowledge Translat G, Lanzhou, Gansu, Peoples R China;[3]corresponding author), Lanzhou Univ, Chinese GRADE Ctr, Lanzhou, Gansu, Peoples R China;[4]corresponding author), WHO Collaborating Ctr Guideline Implementat & Kno, Lanzhou, Gansu, Peoples R China;[5]corresponding author), Gansu Prov Peoples Hosp, Lanzhou, Gansu, Peoples R China.

年份：2019

卷号：56

期号：1

起止页码：7

外文期刊名：ACTA DIABETOLOGICA

收录：;Scopus(收录号：2-s2.0-85047958017);WOS:【SCI-EXPANDED(收录号:WOS:000457388100003)】；

语种：英文

外文关键词：Dipeptidyl peptidase 4 inhibitors; Systematic reviews; Type 2 diabetes mellitus; AMSTAR; GRADE

摘要：AimsTo evaluate the methodological quality of systematic reviews (SRs), and summarize evidence of important outcomes from dipeptidyl peptidase-4 inhibitors (DPP4-I) in treating type 2 diabetes mellitus (T2DM).MethodsWe included SRs of DPP4-I for the treatment of T2DM until January, 2018 by searching the Cochrane Library, PubMed, EMBASE and three Chinese databases. We evaluated the methodological qualities with the AMSTAR (Assessing the Methodological Quality of Systematic Reviews) tool and the GRADE (The Grading of Recommendations Assessment, Development and Evaluation) approach.ResultsSixty-three SRs (a total of 2,603,140 participants) receiving DPP4-I for the treatment of T2DM were included. The results of AMSTAR showed that the lowest quality was a list of studies (included and excluded) item with only one (1.6%) study provided, followed by the providing a priori design item with only four (6.3%) studies conforming to this item, the next were the status of publication (gray literature) used as an inclusion criterion item, with only 18 (28.9%) studies conforming to these items. Only seven (11.1%) studies scored more than nine points in AMSTAR, indicating high methodological quality. For GRADE, of the 128 outcomes, high quality evidence was provided in only 28 (21.9%), moderate in 70 (54.7%), low in 27 (21.1%), and very low in three (2.3%).ConclusionsThe methodological quality of SRs of DPP4-I for type 2 diabetes mellitus is not high and there are common areas for improvement. Furthermore, the quality of evidence level is moderate and more high quality evidence is needed.